Pathologically, the failing prosthesis had several effects. Metal debris from wear of the implant led to a reaction that destroyed the soft tissues surrounding the joint, leaving some patients with long term disability. Ions of cobalt and chromium—the metals from which the implant was made—were also released into the blood and cerebral spinal fluid in some patients.<ref name="fda1">{{cite news | url = http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/MetalonMetalHipImplants/ucm241604.htm | title = FDA. Concerns about metal-on-metal hip implant systems. 2011 | year = 2011 }}</ref>

 
In 2010 a group of [[shareholders]] sued the board for allegedly failing to take action to prevent serious failings and illegalities since the 1990s, including manufacturing problems, bribing officials, covering up adverse effects and misleading marketing for unapproved uses. The judge initially dismissed the case in September 2011, but allowed the plaintiffs opportunity to refile at a later time.<ref>{{cite web|url=http://www.law.du.edu/documents/corporate-governance/independent-director/johnsonjohnson/Opinion-In-re-Johnson-and-Johnson-10-cv-2033-D-NJ-Sept-29-2011.PDF|title=10-cv-2033, D. NJ., Sept. 29, 2011|publisher=}}</ref> In 2012 Johnson and Johnson proposed a settlement with the shareholders, whereby the company would institute new oversight, quality and compliance procedures binding for five years.<ref>[http://www.boston.com/business/healthcare/2012/07/12/shareholders-reach-tentative-deal-lawsuit/6wGyy1rFpcVUR6OEdvYPTL/story.html J&J, shareholders reach tentative deal in lawsuit] By LINDA A. JOHNSON AP Business Writer / July 12, 2012</ref>

 
Juries in several US states have found J&J guilty of concealing the [[adverse effects]] of [[Janssen Pharmaceuticals]]' [[antipsychotic]] medication [[Risperdal]], produced by its unit, in order to promote it to doctors and patients as better than cheaper generics, and of falsely marketing it for treating patients with dementia.<ref name="CNNMoney">{{cite web | url = http://money.cnn.com/2013/11/04/news/companies/johnson-and-johnson-settlement/ | title = Johnson & Johnson to pay $2 billion for false marketing | date = November 4, 2013 | publisher = CNN Money | author = Gregory Wallace |accessdate=November 6, 2013}}</ref>  States that have awarded damages include Texas ($158 million), South Carolina ($327 million), Louisiana ($258 million), and most notably Arkansas ($1.2 billion).<ref>[https://www.nytimes.com/2012/04/12/business/drug-giant-is-fined-1-2-billion-in-arkansas.html?_r=0 J.&J. Fined $1.2 Billion in Drug Case] NY Times, By KATIE THOMAS Published: April 11, 2012</ref>
